TNFAIP8与胃癌耐药关系的初步研究  

Preliminary research in relationship between TNFAIP8 and gastric cancer drug resistance

作　　者：李莉娜[1] 毕志彬[2] 王金胜[1] 

机构地区：[1]长治医学院病理学教研室,长治046000 [2]长治医学院附属和济医院普外科,长治046000

出　　处：《中国免疫学杂志》2016年第7期962-964,969,共4页Chinese Journal of Immunology

基　　金：山西省卫生计生委科研课题(2014140);长治医学院科技创新团队项目(CX201407)

摘　　要：目的:探讨TNFAIP8与胃癌耐药性的关系。方法:选取47例进行新辅助化疗患者手术前后的标本,免疫组化检测TNFAIP8蛋白的表达;Western blot检测胃癌细胞株SGC-7901及其顺铂耐药细胞株SGC7901/DDP中TNFAIP8蛋白表达差异,利用RNA干扰技术降低顺铂耐药细胞株中TNFAIP8的蛋白表达后,MTT检测其对顺铂的敏感性有无变化。结果:TNFAIP8在新辅助化疗前后的表达差异不大,在新辅助化疗无效组中的表达较有效组高(P<0.05);SGC7901/DDP细胞中TNFAIP8蛋白的表达高于SGC7901细胞,siRNA-TNFAIP8质粒转染SGC7901/DDP细胞后蛋白表达显著下降,MTT结果显示降低TNFAIP8蛋白表达,细胞对顺铂的IC50较SGC7901/DDP显著下降(P<0.05),敏感性提高。结论:TNFAIP8参与了胃癌的化疗耐药性。Objective： To explore if there was a correlation between TNFAIP8 and gastric tumor drug resistance. Methods： We collected 47 cases of neoadjuvant chemotherapy,and detected the expression of TNFAIP8 in their tissues before and after surgery by immunohistochemistry. Compared the expression of TNFAIP8 between SGC7901 cell and its cisplatin resistance cell SGC7901-DDP by Western blot,and then we used siRNA technology to decreased its expression,continued to test the susceptibility to cisplatin through MTT. Results： The expression of TNFAIP8 between pre-neoadjuvant and after-neoadjuvant had no difference,but the expression of chemotherapy effectiveness was lower than chemotherapy invalidness（ P〈0. 05）; the expression of SGC7901-DDP cell was also higher than SGC7901 cell; the expression of TNFAIP8 decreased apparently through plasmid transfection of SGC7901-DDP cell,MTT test showed the fewer expression of TNFAIP8 could increase the susceptibility to cisplatin（ P〈0. 05）. Conclusion： TNFAIP8 was involved in chemotherapy resistance of gastric carcinoma.

关 键 词：胃癌 TNFAIP8 耐药 

分 类 号：R735.2[医药卫生—肿瘤]